LifeScience Logistics

After CEO Maselli's ascent, Catalent shakes up operations, taps new execs

After CEO Maselli's ascent, Catalent shakes up operations, taps new execs A new age is dawning at Catalent after the manufacturing juggernaut Tuesday unveiled a new operating structure to home in on its biologics business plus its pharmaceuticals and consumer health arm. | A new age is dawning at Catalent after the manufacturing juggernaut on Tuesday unveiled a new operat...

PCI Pharma Services Announces Major Manufacturing Expansion with $100 Million Investment in New England, Providing Global Capacity to Clients

PCI Pharma Services Announces Major Manufacturing Expansion with $100 Million Investment in New England, Providing Global Capacity to Clients PHILADELPHIA, May 10, 2022--PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced a major expansion of capabilities and capacity in aseptic liquid fill-finish and sterile lyophilization technology, an important manufacturing process c...

Eli Lilly says it's eyeing a potential expedited path to approval for obesity contender tirzepatide.

If Lilly's Alzheimer's prospect proves its merit, it's 'inconceivable' CMS wouldn't cover the med: exec Eli Lilly is feeling pretty secure these days. | Alongside a “long IP runway” for many of Eli Lilly's key drugs, the company has a shot at launching five new medicines over the next year and a half, CEO David Ricks told investors Thursday. Overall, Lilly grew revenue 15% to around $7.8 billion i...

Catalent to Invest $350 Million in Integrated Biologics Drug Substance and Drug Product Manufacturing at Bloomington, Indiana, Facility

Catalent to Invest $350 Million in Integrated Biologics Drug Substance and Drug Product Manufacturing at Bloomington, Indiana, Facility The project will serve the industry’s robust biologics pipeline across various modalities with new bioreactors, syringe filling lines, and additional lyophilization capacity, supported by quality control laboratories and complex automated packaging.

Novartis gets FDA nod to begin making Zolgensma in North Carolina

Novartis gets FDA nod to begin making Zolgensma in North Carolina Novartis can begin producing its spinal muscular atrophy (SMA) gene therapy, Zolgensma, at its North Carolina plant following FDA's approval for a

Two decades and $200 billion: AbbVie's Humira monopoly nears its end

Two decades and $200 billion: AbbVie's Humira monopoly nears its end Biosimilar copies of Humira will arrive in the U.S. beginning early next year, testing both AbbVie and the market potential for knockoff biologic drugs.

The Shifting Course in Logistics Support

The Shifting Course in Logistics Support Today’s ideal pharma third-party logistics (3PL) provider brings the right mix of physical assets, internal expertise, data analytics and strategic partnerships to function as a seamless extension of a manufacturer’s internal operations—no matter what disruptions arise

Flexible hours!
APPLY NOW!

https://www.indeed.com/cmp/Lifescience-Logistics/jobs?q=&l=Whitestown%2C+IN -skip-header-desktop

APPLY NOW!
https://www.indeed.com/cmp/Lifescience-Logistics/jobs?jk=8984667578e5888e&q=&l=Puyallup%2C%20WA&start=0

We are hiring in multiple locations! Scan the QR code or click the link to apply!

Link: https://www.lslog.com/careers

LSL is an EEO Employer

Blackstone Announces Strategic Investment in Life Science Logistics

Blackstone Announces Strategic Investment in Life Science Logistics Blackstone (NYSE: BX) announced today that funds managed by Blackstone Tactical Opportunities (“Blackstone”) have entered into a definitive agreement

https://www.businesswire.com/news/home/20211005005106/en/Life-Science-Logistics-Announces-New-Indiana-Facility-Entry-Into-Raleigh-Durham-to-Meet-Coast-to-Coast-Demand

Life Science Logistics Announces New Indiana Facility, Entry Into Raleigh-Durham to Meet Coast-to-Coast Demand Life Science Logistics Announces New Indiana facility, entry into Raleigh-Durham to meet coast-to-coast pharmaceuticals/medical device demand.